Dyne Therapeutics Inc
DYN14.220USD
+0.980+7.40%
收盤 09/05, 16:00（美東）報價延遲15分鐘
1.63B總市值
虧損本益比TTM
關於 Dyne Therapeutics Inc 公司
Dyne Therapeutics Inc. 是一家臨牀階段的肌肉疾病公司。該公司專注於爲患有遺傳性疾病的人提供改變生活的療法。該公司正在利用其 FORCE 平臺克服肌肉組織輸送和肌肉疾病寡核苷酸療法的侷限性。其 FORCE 平臺療法由寡核苷酸有效載荷組成，旨在針對疾病的遺傳基礎。該公司利用其 FORCE 平臺組建了一系列肌肉疾病療法，包括其在 1 型肌強直營養不良症 (DM1)、杜氏肌營養不良症 (DMD) 和麪肩肱型營養不良症 (FSHD) 方面的領先項目。其療法由三個部分組成：Fab、經過臨牀驗證的連接體和使用連接體連接到 Fab 的寡核苷酸有效載荷。該公司還計劃通過專注於罕見骨骼肌疾病以及心臟和代謝性肌肉疾病的開發工作來擴大其產品組合。
公司簡介
公司代碼DYN
公司名稱Dyne Therapeutics Inc
上市日期Sep 17, 2020
CEOMr. John Cox
員工數量191
證券類型Ordinary Share
年結日Sep 17
公司地址1560 Trapelo Road
城市WALTHAM
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02451
電話17817868230
網址https://dyne-tx.com/
公司代碼DYN
上市日期Sep 17, 2020
CEOMr. John Cox
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Carlo Incerti, M.D.
Dr. Carlo Incerti, M.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
Dr. Doug Kerr
Dr. Doug Kerr
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月15日 週五
更新時間: 8月15日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
10.12%
RA Capital Management, LP
6.83%
Atlas Venture
6.42%
The Vanguard Group, Inc.
5.37%
BlackRock Institutional Trust Company, N.A.
4.63%
其他
66.64%
持股股東
持股股東
佔比
Janus Henderson Investors
10.12%
RA Capital Management, LP
6.83%
Atlas Venture
6.42%
The Vanguard Group, Inc.
5.37%
BlackRock Institutional Trust Company, N.A.
4.63%
其他
66.64%
股東類型
持股股東
佔比
Investment Advisor
29.03%
Investment Advisor/Hedge Fund
24.17%
Venture Capital
21.19%
Hedge Fund
13.77%
Private Equity
3.36%
Research Firm
2.61%
Individual Investor
0.59%
Bank and Trust
0.28%
Pension Fund
0.19%
其他
4.79%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
433
126.04M
90.68%
+6.43M
2025Q1
444
126.02M
110.93%
+6.11M
2024Q4
417
114.24M
101.08%
-7.86M
2024Q3
400
113.88M
111.83%
-6.47M
2024Q2
373
112.89M
113.78%
+7.88M
2024Q1
324
97.50M
111.98%
+21.84M
2023Q4
282
72.67M
118.28%
-4.07M
2023Q3
268
67.80M
111.02%
+90.07K
2023Q2
267
66.99M
114.89%
+4.15M
2023Q1
269
62.13M
106.57%
+3.08M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
10.35M
7.51%
+2.97M
+40.30%
Mar 31, 2025
RA Capital Management, LP
9.71M
7.05%
+3.33M
+52.24%
Mar 31, 2025
Atlas Venture
9.13M
6.62%
+1.11M
+13.86%
Mar 31, 2025
The Vanguard Group, Inc.
7.39M
5.36%
+697.86K
+10.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.26M
4.54%
+96.01K
+1.56%
Mar 31, 2025
Forbion Capital Partners
5.46M
3.96%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.19M
3.77%
-2.39M
-31.52%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.72M
1.97%
+1.37M
+101.71%
Mar 31, 2025
TCG Crossover Management, LLC
2.65M
1.92%
--
--
Mar 31, 2025
State Street Global Advisors (US)
3.61M
2.62%
-107.73K
-2.90%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月2日 週二
更新時間: 9月2日 週二
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
2.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
SPDR S&P Biotech ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Health Innovation Active ETF
0.11%
iShares Biotechnology ETF
0.09%
Optimize Strategy Index ETF
0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.07%
查看更多
iShares Neuroscience and Healthcare ETF
佔比2.06%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.8%
SPDR S&P Biotech ETF
佔比0.27%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.18%
ProShares Ultra Nasdaq Biotechnology
佔比0.12%
Invesco Nasdaq Biotechnology ETF
佔比0.11%
iShares Health Innovation Active ETF
佔比0.11%
iShares Biotechnology ETF
佔比0.09%
Optimize Strategy Index ETF
佔比0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.07%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
